Medical Doctor Program year 2021 Reported 2020–2021 Source: CMS Open Payments, 2026 publication

Carlos Nunez

Internal Medicine Grand Forks, ND Medical Doctor

NPI 1881181287 CMS profile 8800960

1200 S Columbia Rd, Grand Forks, ND 58201

Open in the dashboard

General payments

$378

11 records reported · program years 2020–2021

Research payments

$0

Paid to them · None reported · program years 2020–2021

Ownership & investment interest

$0

None reported

Through program year 2021, Carlos Nunez of Grand Forks, ND is reported in the CMS Open Payments database as having received $378 across 11 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 54th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

2 rows
Year Kind Relative to this record's peak year Amount Records
2021 General $128 6
2020 General $250 5

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Carlos Nunez
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Carlos Nunez were reported at $0. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Carlos Nunez Internal Medicine median Middle half National median
2019 $0 $159 $48–$570 $163
2020 $250 $119 $33–$402 $114
2021 $128 $135 $37–$521 $132
2022 $0 $141 $42–$496 $149
2023 $0 $149 $45–$519 $160
2024 $0 $154 $47–$537 $164
2025 $0 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2020–2021
  1. Gilead Sciences, Inc. $124 1 payment
  2. Lilly USA, LLC $100 3 payments
  3. Amgen Inc. $66 3 payments
  4. Boehringer Ingelheim Pharmaceuticals, Inc. $24 1 payment
  5. Mallinckrodt Hospital Products Inc. $23 1 payment
  6. Salix Pharmaceuticals, a division of Bausch Health US, LLC $21 1 payment
  7. GlaxoSmithKline, LLC. $21 1 payment

Every payment, record by record

What the payments were for General payments · program years 2020–2021
  1. Food and Beverage $378 11 payments
Products named General payments · program years 2020–2021
  1. Epclusa $124 1 payment
  2. OFEV $71 3 payments
  3. Enbrel $49 2 payments
  4. ACTHAR $23 1 payment
  5. TRULANCE $21 1 payment
  6. BENLYSTA $21 1 payment
  7. Otezla $19 1 payment
  8. EVENITY $17 1 payment
  9. Prolia $17 1 payment
  10. TALTZ $15 1 payment
  11. Other $15 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 17 drugs

Part D claims

620

Median for Hospitalist: 109

Drug cost

$27,026

Median for Hospitalist: $6,399

Branded share of claims

18.2%

Median for Hospitalist: 19.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 48 $19,781
Levalbuterol Hcl Generic 15 $1,230
Cefpodoxime Proxetil Generic 35 $1,175
Budesonide Generic 18 $1,022
Atorvastatin Calcium Generic 57 $742
Pantoprazole Sodium Generic 89 $732
Levothyroxine Sodium Generic 54 $596
Carvedilol Generic 49 $403
Clopidogrel Clopidogrel Bisulfate Brand 44 $247
Duloxetine Hcl Generic 40 $246

The 10 drugs with the highest cost, of 17 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,498 Part D prescribers listed as Hospitalist; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 12 billing codes

Paid by Medicare

$90,671

Medicare's payments for the services billed

Medicare patients

296

Average age 74

Services billed

1,116

150 women, 146 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 51%
Heart failure 50%
Chronic kidney disease 49%
Diabetes 45%
Arthritis 45%
Depression 40%
COPD 38%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

11 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in North Dakota

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2021

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record